Related Experiment Video

Updated: Mar 25, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations

Omar Abdel-Rahman1

  • 1Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Lotfy Elsayed Street, PO Box 113331, Cairo, Egypt omar.abdelrhman@med.asu.edu.eg.

Therapeutic Advances in Respiratory Disease
|February 20, 2016
PubMed

Insights

Targeting RAS aberrations in non-small cell lung cancer (NSCLC) with MEK inhibitors shows promise. Clinical trials are evaluating selumetinib and trametinib, particularly in combination therapies, to optimize outcomes for NSCLC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Non-small cell lung cancer (NSCLC) treatment is evolving with targeted therapies.
  • RAS pathway aberrations are key drivers in NSCLC.
  • MEK inhibitors target a principal downstream mediator of RAS aberrations.

Purpose of the Study:

  • To review preclinical and clinical data on targeting RAS aberrations in NSCLC.
  • To focus on the role and optimization of MEK inhibitors.
  • To assess the clinical development of MEK inhibitors like selumetinib and trametinib.

Main Methods:

  • Review of preclinical studies on MEK inhibitor activity in KRAS-mutant NSCLC.
  • Analysis of clinical trial data for selumetinib and trametinib in NSCLC.
  • Examination of combination therapy strategies involving MEK inhibitors.

Main Results:

  • Preclinical data support MEK inhibitor efficacy in KRAS-mutant NSCLC.
  • Selumetinib and trametinib are under clinical investigation, often in combination.
  • Randomized studies are underway to confirm efficacy and positioning.

Conclusions:

  • MEK inhibitors represent a promising therapeutic strategy for NSCLC with RAS aberrations.
  • Combination therapies may enhance outcomes for patients treated with MEK inhibitors.
  • Further clinical validation is ongoing to establish the role of these agents in NSCLC treatment.
Keywords:
KRASMEKlung cancerselumetinibtrametinib

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.4K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.2K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K